The Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis of cancer cell therapies based on information collected from numerous trusted and publicly available sources. We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication.
A global pipeline of cancer cell therapies. 1,011 cancer cell therapies in the current pipeline of 2019, compared to 753 therapies in 2018, are included in the interactive dashboard. The top graph serves as the filter to curate the following two graphs. Seven different classes of cell therapies are defined based on their mechanism of actions. More details and other analyses can be found in the Nature Reviews Drug Discovery article
published on May 30, 2019.
As of today, we have two cancer cell therapy landscape publications:
Explore other immuno-oncology landscapes:
Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.
Subscribe to our email newsletter to receive the latest updates on our landscape analyses.